Biolexis Therapeutics Announces Launch of FIELDS, an AI/ML Drug Discovery Platform

Biolexis is the first company to combine a curated historical wet-lab database, including half-a-million targets of binding data points, with an automated AI/ML-augmented discovery platform. - October 14, 2022

Biolexis Therapeutics Announces Poster Presentation at AACR 2022 Annual Meeting

Biolexis Therapeutics Inc., a leader in bio-tech research and creator of the FIELDS™ process, today announced that data highlighting an orally available, CDK9 selective small molecule inhibitor showing promise in n-Myc-driven neuroendocrine prostate cancers (NEPC) was presented in a poster at... - April 11, 2022

Press Releases 1 - 2 of 2